PT - JOURNAL ARTICLE AU - Grabowski, Frederic AU - Kochańczyk, Marek AU - Lipniacki, Tomasz TI - Omicron strain spreads with the doubling time of 3.2—3.6 days in South Africa province of Gauteng that achieved herd immunity to Delta variant AID - 10.1101/2021.12.08.21267494 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.08.21267494 4099 - http://medrxiv.org/content/early/2021/12/09/2021.12.08.21267494.short 4100 - http://medrxiv.org/content/early/2021/12/09/2021.12.08.21267494.full AB - Omicron, the novel, highly mutated SARS-CoV-2 Variant of Concern (belonging to the Pango lineage B.1.1.529), was first collected on November 8, 2021, in Gauteng province of South Africa. By the end of November 2021 it has spread towards fixation in Gauteng and was detected on all continents. Based on data collected till December 7, 2021, we showed the exponential growth of the Omicron variant over the four-week period in Gauteng (November 8–December 5, 2021) with the doubling time equal 3.38 day [CI 95%: 3.18–3.61 day]. Log–linear regression suggests that the spread began around October 10, 2021, however due to stochasticity in the initial spread this estimate is likely inaccurate. Phylogenetic analysis indicates that the Omicron strain started to diverge in between October 28 and November 5, 2021. This implies that the hidden spread of Omicron before October 10, 2021 (which would suggest slower strain growth) is unlikely. The very short doubling time of Omicron in Gauteng, a province that has reached herd immunity to the Delta variant (implied by the decrease of the weekly number of cases between July and October, 2021, at no significant mobility restrictions), suggests that Omicron will cause abrupt outbreaks of COVID-19 epidemics across the world, and will become the (temporarily) dominant strain.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Science Centre Poland OPUS grant 2018/29/B/NZ2/00668. The funding agency had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe analyzed publicly available genome datasets retrieved from GISAID, https://www.gisaid.org, Community Mobility Reports from Google https://www.google.com/covid19/mobility/, Gauteng province COVID-19 cumulative cases (DSFSI at University of Pretoria, https://github.com/dsfsi/covid19za/tree/master/data, and South African National Institute for Communicable Diseases (NICD) https://www.nicd.ac.za/latest-confirmed-cases-of-covid-19-in-south-africa-23-november-2021 https://www.gisaid.org https://www.google.com/covid19/mobility/ https://github.com/dsfsi/covid19za/tree/master/data https://www.nicd.ac.za/latest-confirmed-cases-of-covid-19-in-south-africa-23-november-2021